Immunovant, Inc.
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
About
CEO
Dr. Peter Salzmann M.B.A., M.D.
Employees
207
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
320 West 37th Street, New York, NY 10018, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 5, 2025 | — | — | — | — |
| Aug 4, 2025 | — | — | — | — |
| Feb 10, 2025 | -0.68 | — | — | — |
| Jan 31, 2025 | -0.68 | — | — | — |
| Nov 7, 2024 | -0.60 | -0.74 | -0.14 | 23.33% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Current Year
(Mar 2025)
|
Next Year
(Mar 2026)
|
||
|---|---|---|---|---|
| Number of analysts | — | 8 | 9 | 8 |
| Average estimate | — | -0.77 | -2.89 | -3.12 |
| Low estimate | — | -0.82 | -3.09 | -3.65 |
| High estimate | — | -0.56 | -2.46 | -2.02 |
| Last year EPS | — | -0.52 | -1.88 | -2.89 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-108.650%
Next qtr. (Mar 2025)
-45.360%
Current year (Mar 2025)
-53.280%
Next year (Mar 2026)
-8.190%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
| Total reported revenue | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 212.93M | 160.26M | 101.81M | 68.60M | 47.93M |
| Selling general and admin | 57.28M | 48.02M | 54.23M | 39.51M | 18.15M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -270.21M | -208.28M | -156.03M | -108.12M | -66.08M |
| Non operating interest income | |||||
| Income | 24.95M | 7.58M | — | — | — |
| Expense | — | — | — | — | 625,000 |
| Other income expense | -13.51M | -10.25M | -781,000 | 328,000 | 412,000 |
| Pretax income | -258.77M | -210.95M | -156.81M | -107.79M | -66.29M |
| Tax provision | 567,000 | 9,000 | -84,000 | -358,000 | 97,000 |
| Net income | -259.34M | -210.96M | -156.73M | -107.43M | -66.39M |
| Basic EPS | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 |
| Diluted EPS | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 |
| Basic average shares | 138.10M | 123.08M | 109.68M | 87.76M | 43.20M |
| Diluted average shares | 138.10M | 123.08M | 109.68M | 87.76M | 43.20M |
| EBITDA | -257.48M | -198.08M | -155.91M | -108.05M | -65.65M |
| Net income from continuing op. | -259.34M | -210.96M | -156.73M | -107.43M | -66.39M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
| Total assets | 666.37M | 405.84M | 515.56M | 412.49M | 109.39M |
| Current assets | |||||
| Cash | — | — | 493.82M | 400.15M | 100.57M |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 635.37M | 376.53M | 493.82M | 400.15M | 100.57M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 5.34M | 700,000 | 12.23M | 596,000 | — |
| Other receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | — | — | 6.25M | 7.72M | 5.46M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 24.90M | 26.92M | 6.25M | 7.72M | 5.46M |
| Non current assets | |||||
| Properties | 595,000 | 1.51M | 2.63M | 3.48M | 65,000 |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | — | — | — | — | — |
| Construction in progress | — | — | — | — | — |
| Leases | — | — | — | — | — |
| Accumulated depreciation | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | — | — | — | — | 246,000 |
| Total liabilities | 48.61M | 43.34M | 45.74M | 21.01M | 15.32M |
| Current liabilities | |||||
| Accounts payable | 7.16M | 1.35M | 18.63M | 2.43M | 1.19M |
| Accrued expenses | 26.56M | 32.89M | 20.12M | 12.02M | 10.08M |
| Short term debt | 138,000 | 1.17M | 1.15M | 1.18M | — |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 14.74M | 7.53M | 4.46M | 3.14M | 859,000 |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | — | 47,000 | 1.22M | 2.24M | — |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 14,000 | 13,000 | 12,000 | 10,000 | 5,000 |
| Retained earnings | -825.68M | -566.35M | -355.39M | -198.66M | -91.23M |
| Other shareholders equity | 1.91M | 852,000 | 404,000 | -298,000 | -16,000 |
| Total shareholders equity | 617.76M | 362.49M | 469.83M | 391.48M | 94.07M |
| Additional paid in capital | 1.44B | 927.98M | 824.80M | 590.43M | 185.31M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -259.34M | -210.96M | -156.73M | -107.43M | -66.39M |
| Depreciation | 231,000 | 193,000 | 126,000 | 65,000 | 21,000 |
| Deferred Taxes | — | — | — | — | — |
| Stock-Based Compensation | 41.12M | 32.30M | 34.24M | 18.82M | 6.96M |
| Other Non-Cash Items | 1.13M | 1.13M | 1.11M | 651,000 | — |
| Accounts Receivable | -4.56M | 12.23M | -11.72M | -1.11M | -83,000 |
| Accounts Payable | 5.78M | -17.12M | 16.25M | 1.25M | 967,000 |
| Other Assets & Liabilities | -1.17M | -1.15M | -1.18M | -798,000 | — |
| Operating Cash Flow | -216.81M | -183.38M | -117.90M | -88.55M | -58.52M |
| Investing Activities | |||||
| Capital Expenditures | -360,000 | -197,000 | -254,000 | -210,000 | -31,000 |
| Net Intangibles | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — |
| Sale of Investments | — | — | — | — | — |
| Investing Cash Flow | -360,000 | -197,000 | -254,000 | -210,000 | -31,000 |
| Financing Activities | |||||
| Long-Term Debt Issuance | — | — | — | — | — |
| Long-Term Debt Payments | — | — | — | -3.19M | -5.00M |
| Other Financing Charges | -6.01M | -272,000 | 200.13M | -140,000 | 109.07M |
| Financing Cash Flow | 466.73M | 70.23M | 200.13M | 313.26M | 141.97M |
| Other Cash Details | |||||
| End Cash Position | 635.37M | 376.53M | 493.82M | 400.15M | 100.57M |
| Income Tax Paid | 509,000 | — | — | 166,000 | 61,000 |
| Interest Paid | — | — | — | — | — |
| Free Cash Flow | -214.59M | -188.39M | -106.37M | -83.54M | -53.39M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Fidelity Growth Company Fund | Nov 30, 2024 | 3,486,978 | 72.91M | 2.05% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 2,117,108 | 44.27M | 1.25% |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 1,663,341 | 34.78M | 0.98% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 1,651,105 | 34.52M | 0.97% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 1,626,419 | 34.01M | 0.96% |
| Price (T.Rowe) Small Cap Stock Fund | Sep 30, 2024 | 1,285,554 | 26.88M | 0.76% |
| Fidelity Growth Company K6 Fund | Nov 30, 2024 | 1,137,064 | 23.78M | 0.67% |
| Vanguard Small Cap Value Index Fund | Sep 30, 2024 | 1,116,120 | 23.34M | 0.66% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 980,601 | 20.50M | 0.58% |
| Fidelity Series Growth Company Fund | Nov 30, 2024 | 915,900 | 19.15M | 0.54% |
Article
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
Feb 7, 2025
Article
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal third quarter ended December 31, 2024.
Feb 6, 2025
Article
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Jan 24, 2025
